Detection of hepatitis c mutants with natural resistance to ns3/4a protease inhibitors in hiv/hcv-coinfected individuals treated with antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 1, 2009, Pages 106-108

  Morsica, Giulia ^a   Bagaglio, Sabrina ^a   Uberti Foppa, Caterina ^a   Galli, Laura ^a   Lazzarin, Adriano ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR PHOSPHATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; BOCEPREVIR; INDINAVIR; ITMN 191; LOPINAVIR; NELFINAVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 3 PROTEINASE INHIBITOR; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 4A PROTEINASE INHIBITOR; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; SAQUINAVIR; TELAPREVIR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; DNA POLYMORPHISM; DRUG POTENTIATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MIXED INFECTION; PRIORITY JOURNAL; VIRUS DETECTION; VIRUS MUTANT;

ADULT; ANTI-HIV AGENTS; CARRIER PROTEINS; DRUG RESISTANCE, VIRAL; FEMALE; GENES, VIRAL; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTEASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS;

EID: 67651148377     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181a02fda     Document Type: Letter

References (10)

1. Lin K, Perni RB, Kwong AD, et al. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob Agents Chemother. 2006;50:1813-1822.
2. Malcolm BA, Liu R, Lahser F, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother. 2006;50: 1013-1020.
3. Bogen SL, Arasappan A, Bennett F. Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication. J Med Chem. 2006;49:2750-2757.
4. Prongay AJ, Guo Z, Yao N. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1, 1-dimethylethyl)amino]carbonyl] amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3- azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structurebased optimization. J Med Chem. 2007;50: 2310-2318.
5. Seiwert SD, Andrews SW, Tan H, et al. Preclinical characterisitics of ITMN-B, an orally active inhibitor of the HCV NS3/4A protease nominated for preclinical development. J Hepatol. 2006;44:S278.
6. Vispo E, Barreiro P, Pineda JA, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther. 2008;13: 429-437.
7. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054-1058.
8. De Francesco R, Carfi A. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent rNA polymerase of the hepatitis C virus. Adv Drug Deliv Rev. 2007; 59:1242-1262. [e-pub August 11, 2007]. Review.
9. Lopez-Labrador FX, Moya A, Gonzàles-Candelas F. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther. 2008;13:481-494.
10. Halfon P, Bourliere M, Khiri G, et al. Mutation rate in hepatitis C virus NS3 protease is not influenced by HIV-1 protease inhibitor therapy. AIDS. 2008;22:1694-1696.